Pravastatin improves uterine and carotid artery function through vascular bed-specific mechanisms in a rat model of excessive hypercholesterolemia in pregnancy

Excessive hypercholesterolemia (eHC) in pregnancy is a risk factor for adverse outcomes, including preeclampsia; however, the underlying mechanisms remain unclear. Uterine artery endothelial dysfunction in eHC is mediated by activation of the toll-like receptor 4 (TLR4)/lectin-like oxidized LDL receptor-1 (LOX-1)/prostaglandin H synthase 1 (PGHS1) pathway. Pravastatin, a cholesterol-lowering drug, reduces the incidence of preeclampsia in high-risk pregnancies due to its pleiotropic effects. Outside of pregnancy, the pleiotropic effects include suppression of TLR4 and LOX-1 signaling. Whether pravastatin improves uterine artery endothelial function in eHC via inhibition of TLR4/LOX-1 is not known. We hypothesized that pravastatin suppresses TLR4/LOX-1 signaling, thereby improving uterine artery endothelial function in eHC pregnancies. Sprague Dawley rats were fed either a control diet or a high cholesterol diet from gestational day (GD) 6-20 and treated with vehicle or pravastatin (5 mg/kg/day) from GD10-20. On GD20, pregnancy outcomes were assessed, and endothelial function in uterine and carotid (a systemic vascular bed that is dysfunctional in postpartum eHC dams) arteries was evaluated using wire myography. In uterine arteries, pravastatin improved blood flow and endothelial function mainly via suppression of TLR4, while also increasing nitric oxide-mediated vasodilation. In carotid arteries, endothelial function was unchanged; however, functional responses to NOS inhibition suggested reduced NO contribution to vasodilation in eHC vehicle-treated dams, accompanied by increased reliance on PGHS2, both of which were normalized in pravastatin-treated dams. These findings demonstrate that pravastatin exerts vascular bed-specific effects and suggest that its use during pregnancy can improve maternal vascular function in eHC pregnancies.

Authors

Institutions

Publication Details

Journal
Clinical Science
Published
2026-11-16
DOI
https://doi.org/10.1042/cs20261476
Primary Topic
Pregnancy and preeclampsia studies
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Pravastatin improves uterine and carotid artery function through vascular bed-specific mechanisms in a rat model of excessive hypercholesterolemia in pregnancy

Murilo Eduardo Graton, Amanda Alves de Oliveira, Raven Kirschenman, Floor Spaans et al.
3 links
Clinical Science
Pregnancy and preeclampsia studies
article

Pravastatin improves uterine and carotid artery function through vascular bed-specific mechanisms in a rat model of excessive hypercholesterolemia in pregnancy

Murilo Eduardo Graton, Amanda Alves de Oliveira, Raven Kirschenman, Floor Spaans, Sandra T. Davidge, Anita Quon, Christy-Lynn M. Cooke
article en

Abstract

Excessive hypercholesterolemia (eHC) in pregnancy is a risk factor for adverse outcomes, including preeclampsia; however, the underlying mechanisms remain unclear. Uterine artery endothelial dysfunction in eHC is mediated by activation of the toll-like receptor 4 (TLR4)/lectin-like oxidized LDL receptor-1 (LOX-1)/prostaglandin H synthase 1 (PGHS1) pathway. Pravastatin, a cholesterol-lowering drug, reduces the incidence of preeclampsia in high-risk pregnancies due to its pleiotropic effects. Outside of pregnancy, the pleiotropic effects include suppression of TLR4 and LOX-1 signaling. Whether pravastatin improves uterine artery endothelial function in eHC via inhibition of TLR4/LOX-1 is not known. We hypothesized that pravastatin suppresses TLR4/LOX-1 signaling, thereby improving uterine artery endothelial function in eHC pregnancies. Sprague Dawley rats were fed either a control diet or a high cholesterol diet from gestational day (GD) 6-20 and treated with vehicle or pravastatin (5 mg/kg/day) from GD10-20. On GD20, pregnancy outcomes were assessed, and endothelial function in uterine and carotid (a systemic vascular bed that is dysfunctional in postpartum eHC dams) arteries was evaluated using wire myography. In uterine arteries, pravastatin improved blood flow and endothelial function mainly via suppression of TLR4, while also increasing nitric oxide-mediated vasodilation. In carotid arteries, endothelial function was unchanged; however, functional responses to NOS inhibition suggested reduced NO contribution to vasodilation in eHC vehicle-treated dams, accompanied by increased reliance on PGHS2, both of which were normalized in pravastatin-treated dams. These findings demonstrate that pravastatin exerts vascular bed-specific effects and suggest that its use during pregnancy can improve maternal vascular function in eHC pregnancies.

Clinical Science
University of Alberta (CA)
Women and Children's Health Research Institute, Canadian Institutes of Health Research
Good health and well-being
Pregnancy and preeclampsia studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon